Oklahoma Senate Bill SB2017

Oklahoma 2026 Regular Session

• Introduced: 2/2/26
• Refer: 2/3/26

Caption

Public health; prohibiting administration of gene-based vaccines until certain date. Emergency.

Summary

SB2017 would create a new section of Oklahoma law defining “gene-based vaccine for infectious diseases” to include vaccines developed using mRNA, modified mRNA, self-amplifying mRNA, or DNA technology, while excluding gene therapy products used to treat cancer or genetic disorders. The bill would prohibit health care providers from administering any such gene-based vaccine to any person in Oklahoma until June 1, 2030. The measure also establishes enforcement consequences for violations. A provider convicted of administering a prohibited vaccine would be guilty of a misdemeanor and subject to a fine of up to $500 for each incident, and the provider could also face disciplinary action from the appropriate licensing board. The bill includes an emergency clause, meaning it would take effect immediately upon passage and approval.

Impact

If enacted, SB2017 would significantly restrict clinical vaccination practices in Oklahoma by barring health care providers from administering mRNA- and DNA-based vaccines for infectious diseases for a defined period. It would add a new provision to Title 63 of the Oklahoma Statutes and create both criminal and professional-licensing penalties for providers who violate the ban. The bill would directly affect physicians, clinics, pharmacies, and other licensed health care providers involved in vaccine administration, and could also affect patient access to certain infectious-disease vaccines statewide.

Sentiment

Based on the bill text and available legislative context, the measure appears to be introduced as a restrictive public health proposal rather than a broadly supported consensus measure. No committee transcript or vote record is available here to show debate or amendments, and the bill’s referral status suggests it was still in early committee consideration. The inclusion of an emergency clause indicates the sponsor viewed the issue as urgent, but the absence of recorded votes or discussion prevents a fuller read on legislative sentiment.

Contention

The main point of contention is the bill’s broad prohibition on gene-based vaccines, especially mRNA COVID-era vaccine technology, which many public health and medical stakeholders would likely view as an overreach into medical practice and vaccine access. Supporters would likely frame the bill as a precautionary public health measure, while opponents would likely argue it conflicts with established vaccine science, limits provider discretion, and could reduce access to approved infectious-disease vaccines. The criminal penalty and licensing-board discipline provisions are also likely to be controversial because they expose providers to both legal and professional consequences for administering covered vaccines.